

31 Jan 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 29 January 2021.

This time we have the latest on [Johnson & Johnson](#)'s coronavirus vaccine, [Novartis AG](#)'s Q4 results, safety issues around one JAK inhibitor, [Eli Lilly and Company](#)'s growth plans, and the latest in the *Scrip Asks* series.

These and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and now on [Spotify Podcasts](#) - and also via smart speakers if one of these channels has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update](#)" - Scrip, 26 Jan, 2021.)

(Also see "[Novartis Holds Out For Happier Second Half Of 2021](#)" - Scrip, 26 Jan, 2021.)

(Also see "[Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms](#)" - Scrip, 27 Jan, 2021.)

(Also see "[CFO Joshua Smiley On Lilly's Next Decade Of Growth](#)" - Scrip, 22 Jan, 2021.)

(Also see "[Scrip Asks...What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings](#)" - Scrip, 25 Jan, 2021.)

[Click here to explore this interactive content online](#) 